RNA - Avidity Biosciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
RNA price evolution
RNA
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $185.38 | $85.94 | $154.18 | $118.96 |
| Short term investments | $410.27 | $456.93 | $422.62 | $467.59 |
| Net receivables | $1.1 | $1.18 | ||
| Inventory | ||||
| Total current assets | $611.31 | $555.49 | $594.53 | $597.15 |
| Long term investments | ||||
| Property, plant & equipment | $16.65 | $17.04 | $15.53 | $16.1 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $17.25 | $17.68 | $16.25 | $16.83 |
| Total investments | $410.27 | $456.93 | $422.62 | $467.59 |
| Total assets | $628.55 | $573.16 | $610.78 | $613.98 |
| Current liabilities | ||||
| Accounts payable | $34.34 | $31.98 | $31.76 | $33.89 |
| Deferred revenue | $69.26 | $1.97 | $3.81 | $5.06 |
| Short long term debt | $3.64 | $3.6 | $3.15 | $3.13 |
| Total current liabilities | $80.68 | $48.72 | $45.24 | $48.09 |
| Long term debt | $6.21 | $6.98 | $6.36 | $6.98 |
| Total noncurrent liabilities | $47.11 | $6.98 | $6.36 | $6.98 |
| Total debt | $9.85 | $10.58 | $9.51 | $10.11 |
| Total liabilities | $127.79 | $55.7 | $51.61 | $55.06 |
| Shareholders' equity | ||||
| Retained earnings | -$570.76 | -$510.32 | -$457.96 | -$410.94 |
| Other shareholder equity | $0.13 | -$1.88 | -$2.67 | -$1.53 |
| Total shareholder equity | $500.76 | $517.47 | $559.18 | $558.91 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $185.38 | $340.65 | $320.7 | $321.71 |
| Short term investments | $410.27 | $270.33 | $85.09 | $6.68 |
| Net receivables | $1.1 | |||
| Inventory | ||||
| Total current assets | $611.31 | $622.94 | $411.14 | $331.68 |
| Long term investments | ||||
| Property, plant & equipment | $16.65 | $15.01 | $15.59 | $1.47 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $17.25 | $15.86 | $16.44 | $2.22 |
| Total investments | $410.27 | $270.33 | $85.09 | $6.68 |
| Total assets | $628.55 | $638.8 | $427.58 | $333.9 |
| Current liabilities | ||||
| Accounts payable | $34.34 | $32.57 | $14.09 | $7.75 |
| Deferred revenue | $69.26 | $6.28 | $11.4 | $15.84 |
| Short long term debt | $3.64 | $3.1 | $1.77 | |
| Total current liabilities | $80.68 | $51.91 | $29.66 | $14.59 |
| Long term debt | $6.21 | $7.58 | $9.96 | $0.94 |
| Total noncurrent liabilities | $47.11 | $8.82 | $16.49 | $13.09 |
| Total debt | $9.85 | $10.69 | $11.73 | $0.94 |
| Total liabilities | $127.79 | $60.73 | $46.15 | $27.68 |
| Shareholders' equity | ||||
| Retained earnings | -$570.76 | -$358.54 | -$184.55 | -$66.54 |
| Other shareholder equity | $0.13 | -$2.7 | -$0.19 | -$0.01 |
| Total shareholder equity | $500.76 | $578.08 | $381.43 | $306.22 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.19 | $2.82 | $2.32 | $2.23 |
| Cost of revenue | ||||
| Gross Profit | $2.19 | $2.82 | $2.32 | $2.23 |
| Operating activities | ||||
| Research & development | $52.82 | $47.71 | $42.67 | $47.77 |
| Selling, general & administrative | $16.12 | $13.73 | $12.28 | $12.06 |
| Total operating expenses | $68.94 | $61.44 | $54.95 | $59.83 |
| Operating income | -$66.74 | -$58.63 | -$52.63 | -$57.6 |
| Income from continuing operations | ||||
| EBIT | -$60.44 | -$52.36 | -$47.02 | -$52.39 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$60.44 | -$52.36 | -$47.02 | -$52.39 |
| Income (for common shares) | -$60.44 | -$52.36 | -$47.02 | -$52.39 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.56 | $9.22 | $9.33 | $6.79 |
| Cost of revenue | ||||
| Gross Profit | $9.56 | $9.22 | $9.33 | $6.79 |
| Operating activities | ||||
| Research & development | $190.97 | $150.4 | $101.18 | $37.6 |
| Selling, general & administrative | $54.19 | $37.73 | $26.2 | $13.46 |
| Total operating expenses | $245.16 | $188.14 | $127.38 | $51.06 |
| Operating income | -$235.6 | -$178.91 | -$118.05 | -$44.28 |
| Income from continuing operations | ||||
| EBIT | -$212.22 | -$174 | -$118.01 | -$44.15 |
| Income tax expense | ||||
| Interest expense | $0.21 | |||
| Net income | ||||
| Net income | -$212.22 | -$174 | -$118.01 | -$44.35 |
| Income (for common shares) | -$212.22 | -$174 | -$118.01 | -$44.35 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$60.44 | -$52.36 | -$47.02 | -$52.39 |
| Operating activities | ||||
| Depreciation | $1.44 | $1.3 | $1.26 | $1.08 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.85 | $9.82 | $9.45 | $9.1 |
| Total cash flows from operations | $16.5 | -$36.79 | -$49.81 | -$48.97 |
| Investing activities | ||||
| Capital expenditures | -$0.86 | -$0.92 | -$0.62 | -$1.82 |
| Investments | $51.9 | -$30.56 | $46.67 | -$193.86 |
| Total cash flows from investing | $51.04 | -$31.48 | $46.05 | -$195.68 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $31.89 | $0.04 | $38.97 | $22.96 |
| Net borrowings | ||||
| Total cash flows from financing | $31.89 | $0.04 | $38.97 | $22.96 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $99.43 | -$68.23 | $35.21 | -$221.69 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$212.22 | -$174 | -$118.01 | -$44.35 |
| Operating activities | ||||
| Depreciation | $5.08 | $1.39 | $0.64 | $0.37 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $38.22 | $27.14 | $17.06 | $4.31 |
| Total cash flows from operations | -$119.06 | -$136.27 | -$94.81 | -$37.12 |
| Investing activities | ||||
| Capital expenditures | -$4.23 | -$2.82 | -$3.74 | -$1.09 |
| Investments | -$125.84 | -$187.13 | -$78.78 | -$6.69 |
| Total cash flows from investing | -$130.07 | -$189.96 | -$82.52 | -$7.79 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $93.86 | $346.17 | $176.32 | $274.52 |
| Net borrowings | -$4.68 | |||
| Total cash flows from financing | $93.86 | $346.17 | $176.32 | $272.04 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$155.27 | $19.95 | -$1.01 | $227.13 |
News
Fundamentals
| Market cap | $1.92B |
|---|---|
| Enterprise value | $1.74B |
| Shares outstanding | 79.28M |
| Revenue | $9.56M |
|---|---|
| EBITDA | -$207.14M |
| EBIT | -$212.22M |
| Net Income | -$212.22M |
| Revenue Q/Q | -20.80% |
| Revenue Y/Y | 3.64% |
| P/E ratio | -9.02 |
|---|---|
| EV/Sales | 181.98 |
| EV/EBITDA | -8.40 |
| EV/EBIT | -8.20 |
| P/S ratio | 200.34 |
| P/B ratio | 3.83 |
| Book/Share | 6.32 |
| Cash/Share | 2.34 |
| EPS | -$2.68 |
|---|---|
| ROA | -34.98% |
| ROE | -39.74% |
| Debt/Equity | 0.26 |
|---|---|
| Net debt/EBITDA | 0.28 |
| Current ratio | 7.58 |
| Quick ratio | 7.58 |